RORβ: A Novel Oncology Target

Orphagen has explored the potential of the orphan nuclear receptor retinoid-related orphan receptor beta (RORβ) in diverse therapeutic areas. Our antagonists are active in preclinical models, and we are open to collaborations to investigate the properties of RORβ ligands.

We have successfully identified potent ligands for RORβ, including both antagonists and agonists. Our research has encompassed both in vitro and in vivo pharmacology. We find that ROR antagonists can potently modulate gene expression, as evidenced in our studies involving the retina and a small cell lung carcinoma (SCLC) cell line.

Based on genomic findings in oncology, RORβ antagonists could be effective in SCLC and certain leukemias. Research in these areas continues.

At Orphagen, our commitment to the hunt for novel targeted therapies is embodied in our exploration of RORβ antagonist pharmacology.